A 1-year drug utilization evaluation of protamine in hospitalized patients to identify possible future roles of heparin and low molecular weight heparin reversal agents

Journal of Thrombosis and Thrombolysis

Volumn 37, Issue 3, 2014, Pages 271-278

  Mahan, Charles E ^a  

^a UNIVERSITY OF NEW MEXICO   (United States)

Author keywords

Delparantag (PMX 60056); Low molecular weight heparin; Major bleeding; Protamine; Reversal agents; Unfractionated heparin

Indexed keywords

DELPARANTAG; DESMOPRESSIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; PLACEBO; PROTAMINE SULFATE; HEPARIN ANTAGONIST; PROTAMINE;

ABDOMINAL SURGERY; ANTICOAGULATION; AORTA ARCH SYNDROME; ARTICLE; CORONARY ARTERY BYPASS GRAFT; DIALYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG USE; ELECTROPHYSIOLOGICAL PROCEDURES; FEMALE; GROIN HEMATOMA; HEART CATHETERIZATION; HEART VALVE SURGERY; HOSPITAL PATIENT; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; PATIENT CARE; PATIENT SAFETY; PHASE 1 CLINICAL TRIAL (TOPIC); POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; TRANSCATHETER AORTIC VALVE IMPLANTATION; ANIMAL; CARDIOVASCULAR DISEASES; HOSPITAL ORGANIZATION;

ANIMALS; CARDIOVASCULAR DISEASES; HEPARIN ANTAGONISTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; MALE; MEDICATION SYSTEMS, HOSPITAL; PROTAMINES; RETROSPECTIVE STUDIES;

EID: 84898440134     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-013-0927-7     Document Type: Article

References (45)

1. Garcia DA, Baglin TP, Weitz JI, Samama MM (2012) Parenteral anticoagulants: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e24S-e43S
2. Weitz JI, Eikelboom JW, Samama MM (2012) New antithrombotic drugs: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e120S-e151S
3. Douketis JD, Spyropoulos AC, Spencer FA et al (2012) Perioperative management of antithrombotic therapy. Chest 141(2 Suppl):e326S-e350S
4. http://www.drugs.com/mmx/protamine-sulfate.html. Accessed 20 Mar 2011. Protamine package insert
5. Hirsh J, Bauer KA, Donati MB, Gould M, Samama MM, Weitz JI (2008) Parenteral anticoagulants. Chest 133(6 Suppl):141S-159S
6. Schulman S, Angeras U, Bergqvist D, Eriksson B, Lassen MR, Fisher W (2010) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in surgical patients. J Thromb Haemost 8(1):202-204
7. Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692-694 (Pubitemid 41647882)
8. Bjornaas MA, Jacobsen EM, Jacobsen D (2010) Nonfatal self-poisoning with LMW heparin and the use of antidote. Thromb Res 126(5):e403-e405
9. Chawla LS, Moore G, Seneff MG (2004) Incomplete reversal of enoxaparin toxicity by protamine: implications of renal insufficiency, obesity, and low molecular weight heparin sulfate content. Obes Surg 14(5):695-698 (Pubitemid 38716594)
10. Farooq V, Hegarty J, Chandrasekar T et al (2004) Serious adverse incidents with the usage of low molecular weight heparins in patients with chronic kidney disease. Am J Kidney Dis 43(3):531-537 (Pubitemid 38298212)
11. Makris M, Hough RE, Kitchen S (2000) Poor reversal of low molecular weight heparin by protamine. Br J Haematol 108(4):884-885 (Pubitemid 30304529)
12. http://clinicaltrials.gov/ct2/show/NCT00715455?term=regado&rank=2. Accessed 4 April 2011
13. Shenoy S, Harris RB, Sobel M (1999) Development of heparin antagonists with focused biological activity. Curr Pharm Des 5(12):965-986 (Pubitemid 30014006)
14. Chan S, Kong M, Minning DM, Hedner U, Marder VJ (2003) Assessment of recombinant factor VIIa as an antidote for bleeding induced in the rabbit by low molecular weight heparin. J Thromb Haemost 1(4):760-765
15. Mecca T, Consoli GM, Geraci C, La Spina R, Cunsolo F (2006) Polycationic calix[8]arenes able to recognize and neutralize heparin. Org Biomol Chem 4(20):3763-3768 (Pubitemid 44536088)
16. Cushing DJ, Cooper WD, Cohen ML, McVoy JR, Sobel M, Harris RB (2010) Reversal of heparin-induced increases in aPTT in the rat by PM102, a novel heparin antagonist. Eur J Pharmacol 635(1-3):165-170
17. Gale AJ, Elias DJ, Averell PM et al (2011) Engineered virus-like nanoparticles reverse heparin anticoagulation more consistently than protamine in plasma from heparin-treated patients. Thromb Res 128(4):e9-e13
18. Andrade SA, Carrijo-Carvalho LC, Peceguini LA et al (2012) Reversal of the anticoagulant and anti-hemostatic effect of low molecular weight heparin by direct prothrombin activation. Braz J Med Biol Res 45(10):929-934
19. Condac E, Strachan H, Gutierrez-Sanchez G et al (2012) The C-terminal fragment of axon guidance molecule Slit3 binds heparin and neutralizes heparin's anticoagulant activity. Glycobiology 22(9):1183-1192
20. Bianchini EP, Fazavana J, Picard V, Borgel D (2011) Development of a recombinant antithrombin variant as a potent antidote to fondaparinux and other heparin derivatives. Blood 117(6):2054-2060
21. Zhou X, Li L, Linhardt RJ, Liu J (2013) Neutralizing the anticoagulant activity of ultra-low molecular weight heparins using N-acetylglucosamine 6-sulfatase. FEBS J. doi:10.1111/febs.12169
22. http://www.portola.com/PRT4445-Fxa-Inhibitor-Antidote. Accessed 4 Mar 2013
23. Cohen MG, Purdy DA, Rossi JS et al (2010) First clinical application of an actively reversible direct factor IXa inhibitor as an anticoagulation strategy in patients undergoing percutaneous coronary intervention. Circulation 122(6):614-622
24. http://clinicaltrials.gov/ct2/show/results/NCT00715455?term= reversal+and+heparin&rank=1 Reg1 system. Accessed 5 Feb 2013
25. Povsic TJ, Cohen MG, Mehran R, et al. (2011) A randomized, partially blinded, multicenter, active-controlled, dose-ranging study assessing the safety, efficacy, and pharmacodynamics of the REG1 anticoagulation system in patients with acute coronary syndromes: design and rationale of the RADAR Phase IIb trial. Am Heart J. 161(2):261-268 2011 e261-262
26. Povsic TJ, Vavalle JP, Aberle LH, et al.(2012) A Phase 2, randomized, partially blinded, active-controlled study assessing the efficacy and safety of variable anticoagulation reversal using the REG1 system in patients with acute coronary syndromes: results of the RADAR trial. Eur Heart J. Aug 2 2012
27. Povsic TJ, Wargin WA, Alexander JH et al (2011) Pegnivacogin results in near complete FIX inhibition in acute coronary syndrome patients. Eur Heart J 32(19):2412-2419
28. McAllister, R. E. (2010) Heparin-Antagonist PMX-60056 Rapidly and Completely Reverses Heparin Anticoagulation in Man. American Heart Association
29. McAllister RE (2010) Reversal of heparin by novel synthetic antagonist PMX-60056 exhibits a linear dose-response relationship. Poster Presentation, American Society of Hematology annual meeting and exposition
30. McAllister, R. E. Heparin-Antagonist PMX-60056(2010) Rapidly Reverses Anti-Xa and aPTT Effects of Tinzaparin in Man. Poster Presentation at American Heart Association
31. Kuziej J, Litinas E, Hoppensteadt DA et al (2010) In vivo neutralization of unfractionated heparin and low-molecular-weight heparin by a novel salicylamide derivative. Clin Appl Thromb Hemost 16(4):377-386
32. Warkentin TE, Greinacher A, Koster A, Lincoff AM (2008) Treatment and prevention of heparin-induced thrombocytopenia. Chest 133(6 Suppl):340S-380S
33. Baroletti S, Piovella C, Fanikos J, Labreche M, Lin J, Goldhaber SZ (2008) Heparin-induced thrombocytopenia (HIT). Thromb Haemost 100(6):1130-1135
34. Creekmore FM, Oderda GM, Pendleton RC, Brixner DI (2006) Incidence and economic implications of heparin-induced thrombocytopenia in medical patients receiving prophylaxis for venous thromboembolism. Pharmacotheraphy 26(10):1438-1445 (Pubitemid 44521729)
35. American Heart Association.(2006) Heart disease and stroke statistics update. Dallas: American Heart Association
36. Leon MB, Smith CR, Mack M et al (2010) Transcatheter aortic-valve implantation for aortic stenosis in patients who cannot undergo surgery. N Engl J Med 363(17):1597-1607
37. Anderson FA Jr, Zayaruzny M, Heit JA, Fidan D, Cohen AT (2007) Estimated annual numbers of US acute-care hospital patients at risk for venous thromboembolism. Am J Hematol 82(9):777-782 (Pubitemid 350194504)
38. Mahan CE, Borrego ME, Woersching AL et al (2012) Venous thromboembolism: annualised United States models for total, hospital-acquired and preventable costs utilising long-term attack rates. Thromb Haemost 108(2):291-302
39. Hirsh J, Hoak J (1996) Management of deep vein thrombosis and pulmonary embolism. a statement for healthcare professionals. Council on Thrombosis (in consultation with the Council on Cardiovascular Radiology), American Heart Association. Circulation 93(12):2212-2245
40. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ (2008) Antithrombotic therapy for venous thromboembolic disease. Chest 133(6 Suppl):454S-545S
41. Spyropoulos AC, Hurley JS, Ciesla GN, de Lissovoy G (2002) Management of acute proximal deep vein thrombosis. Chest 122(1):108-114
42. Mahan CE, Spyropoulos AC (2011) Perioperative antithrombotic management and anticoagulant bridging. Can J Gen Intern Med 6(1 Suppl):13-21
43. Go AS, Hylek EM, Phillips KA et al (2001) Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention. JAMA 285(18):2370-2375
44. Douketis JD, Berger PB, Dunn AS et al (2008) The perioperative management of antithrombotic therapy. Chest 133(6 Suppl):299S-339S
45. Weitz JI, Hirsh J, Samama MM (2008) New antithrombotic drugs. Chest 133(6 Suppl):234S-256S